OPK supply chain intelligence for OPKO Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RUEN-HUI-BIOPHARMACEUTICALS-INC | RUEN-HUI-BIOPHARMACEUTICALS-INC | 92% | Ruen-Hui assumed the Company's obligations under an exclusive license agreement with Academia Sinica in exchange for an upfront payment of $150,000, a number of potential milestone payments up to $1 … |
| ENTERA-BIO-LTD | ENTERA-BIO-LTD | 85% | The Company and its subsidiary, OPKO Biologics, entered into an amended and restated collaboration and license agreement with Entera Bio Ltd. ("Entera"), expanding our existing partnership to include… |
| ASND | Ascendis Pharma A/S | 72% | aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: Reciprocal relationship from OPK graph: aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substant… |
| NIMU | Non-Invasive Monitoring Systems, Inc. | 72% | Reciprocal relationship from NIMU graph: Item 13. Certain Relationships and Related Transactions, and Director Independence. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS Dr. Frost is a director and… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from OPK graph: aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substanti… |
| NVO | Novo Nordisk A/S | 72% | aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| ONCO | Onconetix, Inc. | 72% | Reciprocal relationship from ONCO graph: me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and gre… |
| PFE | Pfizer Inc. | 72% | Reciprocal relationship from PFE graph: . We promote our products to healthcare providers and patients consistent with applicable laws. Through our marketing organizations, we explain the approved us… |
| SNYNF | Sanofi | 72% | $ million from gross profit share and royalty payments for both NGENLA (Somatrogon) and Pfizer's Genotropin® (Somatropin), $ million from the BARDA Contract, a $ million milestone payment from Merck … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from OPK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from OPK graph: $ million from gross profit share a… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NEXTPLAT | NEXTPLAT | 90% | The Company and NextPlat amended the agreement in October 2024 to extend the term of the agreement to 2026, and permit NextPlat to launch an online storefront on additional e-commerce platforms throu… |
| NIMU | Non-Invasive Monitoring Systems, Inc. | 90% | Reciprocal relationship from NIMU graph: One of those related parties, OPKO Health, Inc. ("OPKO") and the Company are under common control and OPKO has a one percent ownership interest in the Company… |
| OPKO-HEALTH-EUROPE-SLU | OPKO-HEALTH-EUROPE-SLU | 90% | The Company launched an OPKO Health-branded online storefront on the Alibaba Group Holding Limited Tmall Global e-commerce platform in China, featuring an assortment of nutraceutical and veterinary p… |
| LLY | Eli Lilly and Company | 85% | Reciprocal relationship from LLY graph: Reciprocal relationship from OPK graph: 6, through its subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and C… |
| LLY | Eli Lilly and Company | 85% | 6, through its subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and Company (“Eli Lilly”) to develop and commercialize certain oxyntomodulin-based co… |
| ASND | Ascendis Pharma A/S | 72% | aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ASND graph: Reciprocal relationship from OPK graph: Reciprocal relationship from ASND gra… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NVO graph: Reciprocal relationship from OPK graph: Reciprocal relationship from NVO graph:… |
| NVO | Novo Nordisk A/S | 72% | aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources, larger research and development staf… |
| ONCO | Onconetix, Inc. | 72% | Reciprocal relationship from ONCO graph: me of which possess substantially greater financial, selling, logistical and laboratory resources, more experience in dealing with third-party payors, and gre… |
| SNYNF | Sanofi | 72% | stinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific protein antibody for influenza or another pathogen is also a separate performance … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from OPK graph: stinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific … |
| WGS | GeneDx Holdings Corp. | 72% | Reciprocal relationship from WGS graph: Reciprocal relationship from OPK graph: Reciprocal relationship from WGS graph: Reciprocal relationship from OPK graph: t, and lower costs related to Somatrogo… |
| WGS | GeneDx Holdings Corp. | 72% | t, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization. Contingent consideration . Conting… |
| WGSWW | WGSWW | 72% | Reciprocal relationship from WGSWW graph: Reciprocal relationship from OPK graph: lated to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has receive… |
| WGSWW | WGSWW | 72% | lated to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization. Contingent consideration . Contingent consideration for… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| OPK-DEBT | Debt stack $396.9M | 90% | Market cache reports total debt of $396.9M. |
| OPK-DEBT-11566 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| OPK-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP | Rubric Capital Management LP | 90% | 13F overlay lists Rubric Capital Management LP as top holder; 238 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 |